Sarepta's (SRPT) SRP-5051 Toxicity Issue not "Program-Killing" - Cowen Reiterates Outperform Rating on Stock
Tweet Send to a Friend
Cowen analyst Ritu Baral reiterated an Outperform rating and $114.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), after the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
